Program Summary
Dr. Mohan Viswanathan reviews the limitations of presently available drugs for atrial fibrillation and presents information on potential mechanisms for new mixed channel and atrial selective antiarrhythmic drugs, including Vernakalant and Ranolazine.
Target Audience
This program is intended for a professional audience.
- Cardiac electrophysiologists
- Cardiology and cardiac electrophysiology fellows
- Cardiac surgeons
- Other cardiologists and radiologists
Learning Objectives
Upon completion of this educational activity, participants will be able to:
- List potential limitations of presently available antiarrhythmic drugs.
- Restate the cellular targets of new drugs and contrast with conventional drugs
- Recall the efficacy of Vernakalant demonstrated in the CRAFT and ACT trials and the theoretical limitations of the mechanism in action.
- Describe the mechanism of action of Ranolazine and how this is antiarrhythmic in nature.
Faculty
Mohan N. Viswanathan, MD
University of California-San Francisco
San Francisco, CA
Author
Mark S. Kremers, MD
Mid-Carolina Cardiology
Charlotte, NC
Accreditation
The Heart Rhythm Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Continuing Medical Education (CME)
The Heart Rhythm Society designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The AMA has determined that physicians not licensed in the USA who participate in this CME activity are eligible for AMA PRA Category 1 CreditsTM.
Continuing Education (CE) for Nurses
The Heart Rhythm Society is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
It has been assigned code 7M7R3X-PRV-09-04.
A maximum of 1.0 credit hours are available for this educational activity.
View Webcast
New Ion Channel Agents for Rhythm Control of Atrial Fibrillation
Required Hardware and Software
- Computer Screen with USB Drive Screen resolution of 1024x786 or larger
- Sound card and speakers/headphones
- Operating System Requirement: Windows Vista; Windows XP Service Pack 2, Windows 7 Intel® Pentium® III 450MHz or faster processor (or equivalent) 128MB or RAM Mac OS Apple Mac OS X 10.4.8 or above Intel Core TM Duo 1.83GHz or faster processor 128MB of RAM Plug-in
Copyright © 2009 Heart Rhythm Society.
|
Supported by an educational grant from:
|
 |
